


Cosentyx Derm - Digital dosing schedule - HCP

[Prescribing information](#)

Image



Image



 **Cosentyx**[®]
secukinumab

Digital dosing schedule

Cosentyx[®] (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy.^{1,2}

[Full indications for Cosentyx can be found here](#)

Please refer to the Summary of Product Characteristics (SmPC) for further information. The GB SmPC can be found [here](#), and the NI SmPC can be found [here](#).

Help your newly initiated Cosentyx patients keep track of their treatment with a digital dosing schedule. As a healthcare professional, you can download the relevant documents and fill in the patient's planned injection dates.

Share the completed file with your patients and they can simply tick the circles after they administer their Cosentyx dose, as shown in the example below:

Image

Cosentyx (secukinumab) patient dosing schedule for Psoriasis

Name:

Prescribed dose: mg


Keep track of your Cosentyx treatment using the dosing schedule below. Your healthcare professional should have already entered your **planned injection dates**.

You can **tick the clickable circles** after administering Cosentyx®, or alternatively print the document to keep track by hand.


*Please note that the clickable function may not work on some devices.

Tick the circle when you've had your treatment on the planned date.

Your healthcare professional has already entered your planned injection dates here.



This is your last weekly dose; the injections will now be monthly.



Treatment continues once monthly. Consult your healthcare professional for further planned injection dates.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.

This leaflet is intended for UK patients who have been prescribed Cosentyx. Not for further distribution.

This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd.
UK | March 2023 | 252771-1

Choose the right schedule for your patients based on Cosentyx dosage and indication, by

using the resources below.

Please note that these resources are designed for optimal use on desktop or tablet. Functionality may be restricted on some devices, including mobile.

Do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only.

Image

Cosentyx[®]
secukinumab

NOVARTIS

Cosentyx (secukinumab) patient dosing schedule for Psoriasis

Name: Prescribed dose: mg

Keep track of your Cosentyx treatment using the dosing schedule below. Your healthcare professional should have already entered your planned injection dates.

You can tick the clickable circles after administering Cosentyx[®], or alternatively print the document to keep track by hand.

*Please note that the clickable function may not work on some devices.

Tick the circle when you've had your treatment on the planned date. Your healthcare professional has already entered your planned injection dates here.

Week 0 1 2 3 4

Month 1

This is your last weekly dose, the injections will now be monthly.

Month 7 6 5 4 3 2

Month 8 9 10 11 12

Treatment continues once monthly. Consult your healthcare professional for further planned injection dates.

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.youryellowcard.co.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
This leaflet is intended for UK patients who have been prescribed Cosentyx. Not for further distribution.
This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd.
UK | March 2023 | 262775-3

Adult psoriasis (PsO) dosing

PDF

[Download](#)

Image


Cosentyx (secukinumab) 2 weekly dosing schedule for adult patients with plaque psoriasis with a body weight of 90 kg or higher

Name: Prescribed dose:

Keep track of your Cosentyx treatment using the dosing schedule below. Your healthcare professional should have already entered your planned injection dates.

You can tick the clickable circles after administering Cosentyx*, or alternatively print the document to keep track by hand. *Please note that the clickable function may not work on some devices.

Tick the circle when you've had your treatment on the planned date.



Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.ukhsa.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.

This resource is only intended for adult patients in the UK with plaque psoriasis with a body weight of 90 kg prescribed Cosentyx. Not for further distribution.

This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd. UK (March 2023) 269237

≥90 kg Adult psoriasis (PsO)

PDF

[Download](#)

Image


Cosentyx (secukinumab) patient dosing schedule for paediatric psoriasis

Name: Prescribed dose:

Keep track of your Cosentyx treatment using the dosing schedule below. Your healthcare professional should have already entered your planned injection dates.

You can tick the clickable circles after administering Cosentyx*, or alternatively print the document to keep track by hand.

*Please note that the clickable function may not work on some devices.



Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.youryellowcard.co.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

This leaflet is intended for UK patients who have been prescribed Cosentyx. Not for further distribution.

This resource has been produced and funded by Novartis Pharmaceuticals UK Ltd.
UK | March 2023 | 250242

Paediatric psoriasis (PsO)

PDF

[Download](#)

Image

PsO dosing

Therapeutic indications^{1,2}

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic

arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.^{1,2}

AS, ankylosing spondylitis; ERA, enthesitis-related arthritis; HS, hidradenitis suppurativa; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC, summary of product characteristics.

References

1. Cosentyx® (secukinumab) GB Summary of Product Characteristics.
2. Cosentyx® (secukinumab) NI Summary of Product Characteristics.

UK | November 2024 | FA-11210377

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

<https://prod.pro.novartis.com/uk-en/medicines/dermatology/cosentyx/hcp-resources/digital-dosing-schedule>